TuHURA Biosciences (NASDAQ:HURA) Stock Breaks Below 200-Day Moving Average - Here's What Happened

TuHURA Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • TuHURA Biosciences shares fell below their 200-day moving average, reaching $1.85 and last trading at $1.93, down 6.3%. The company has a market capitalization of approximately $123 million.
  • Analyst sentiment remains generally positive, with five Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and a $9.00 price target. HC Wainwright and Citizens JMP set targets of $10 and $9, respectively.
  • The clinical-stage biotechnology company is developing cancer immunotherapies, led by its investigational intratumoral treatment IFx-2. Its latest quarterly loss of $0.14 per share was slightly better than analysts’ $0.15 estimate.
  • MarketBeat previews top five stocks to own in December.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report)'s share price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.96 and traded as low as $1.85. TuHURA Biosciences shares last traded at $1.93, with a volume of 519,359 shares changing hands.

Analysts Set New Price Targets

HURA has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday. Citizens Jmp reaffirmed a "market outperform" rating and issued a $9.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Check Out Our Latest Report on HURA

TuHURA Biosciences Stock Down 6.3%

The stock's 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.96. The firm has a market cap of $123.00 million, a P/E ratio of -3.57 and a beta of -0.21. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. As a group, research analysts forecast that TuHURA Biosciences, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $33,000. Merck & Co. Inc. purchased a new position in TuHURA Biosciences in the 2nd quarter worth approximately $45,501. Sanctuary Advisors LLC bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $49,000. Deutsche Bank AG bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $52,000. Finally, Hsbc Holdings PLC bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $69,000. Institutional investors own 0.62% of the company's stock.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA's lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TuHURA Biosciences Right Now?

Before you consider TuHURA Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.

While TuHURA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines